Whalesbook
Market Slumps as Oil Prices Spike
Indian equity markets faced significant pressure on April 23, 2026, as the Sensex fell below 78,000 and the Nifty 50 dropped below 24,200. This broad-based decline was largely due to a sharp rise in crude oil prices, surpassing $100 per barrel, alongside a wider sell-off across Asian markets. Amidst this challenging backdrop, however, select stocks showed notable strength, rising significantly with record trading volumes, indicating investor interest separate from the market's overall mood.
IRM Energy, Piramal Pharma Stand Out with Record Volumes
IRM Energy, a small-cap integrated energy solutions provider, saw its share price surge by over 15% in the first half of Thursday's session. By 11:30 AM, trading volumes on the NSE crossed the 3 crore mark, a record for the stock. This surge occurred as the company operates within India's dynamic energy sector, navigating increased demand, grid constraints, and a shift towards cleaner energy sources.
Piramal Pharma Limited also saw strong trading activity, with its share price gaining more than 7%. Total traded volume on the NSE surpassed 3.10 crore shares by 11:34 AM, marking its highest single-day volume since March 2025. This momentum builds ahead of its scheduled announcement of audited financial results for the quarter and fiscal year ended March 31, 2026, on April 28. The pharmaceutical sector, meanwhile, is projected for strong growth driven by domestic demand and expanding export markets.
IRM Energy: Valuation, Growth, and Risks
IRM Energy, a city gas distribution (CGD) company, has seen its valuation moving from 'expensive' to 'fair' as of early January 2026, with a Price-to-Earnings (P/E) ratio around 19.30-21.60 times as of April 2026. Analysts have a "BUY" rating with an average 12-month target of ₹402.00, suggesting potential upside. The company benefits from operating in authorized geographical areas (GAs) where it holds monopoly rights for compressed natural gas (CNG) and piped natural gas (PNG) supply. Despite its small-cap status, the company is nearly debt-free, a strong point for financial stability. However, its Return on Equity (ROE) remains subdued at approximately 4-7%. Furthermore, the company's Price/Earnings to Growth (PEG) ratio is currently zero, potentially indicating a lack of earnings growth or insufficient data, which could deter growth-focused investors. Past analyst reports included downgrades, advising caution.
Piramal Pharma: Analyst Optimism Meets Financial Headwinds
Piramal Pharma operates in a pharmaceutical sector poised for substantial growth, expected to reach $120-$130 billion by 2030, fueled by innovation, generics, and global demand. Analysts overwhelmingly rate Piramal Pharma a "Strong Buy", with an average 12-month target of ₹200-₹228 INR, suggesting over 30% potential upside. The company boasts a diversified portfolio and global manufacturing footprint. However, current financial figures show a contrast: its trailing twelve months (TTM) P/E ratio is negative (ranging from -120.23 to -135.95), indicating losses, and its ROE is similarly negative or low (-0.55% to -2.03%). While Return on Capital Employed (ROCE) is a modest 2.66%-6.45%, and its market capitalization stands around ₹20,000 Cr, these figures are juxtaposed against high debt relative to EBITDA, raising concerns about its fundamental profitability despite the positive analyst outlook. Investors will closely watch the upcoming report for signs of a return to profitability.
Outlook for Both Firms
Analysts remain largely optimistic regarding both companies' prospects. For IRM Energy, the average 12-month price target of ₹402.00 suggests significant upside potential, supported by its strategic market position in CGD. Piramal Pharma, despite current financial strains, has an average target price around ₹200-₹228 INR, driven by strong analyst conviction in its long-term recovery and growth narrative within the expanding Indian pharmaceutical market. Sector-wide growth projections for both energy and pharmaceuticals in India remain robust, driven by increasing domestic demand and supportive government policies.